Track TG Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

TG Therapeutics, Inc. TGTX · Stock Open TG Therapeutics, Inc. in new tab

64.51 USD
P/E
21.75
EPS
2.75
P/B
14.05
ROE
100.28
Beta
1.81
Target Price
69.71 USD
TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

🧾 Earnings Recap – Q3 2026

TG Therapeutics raised 2026 global revenue guidance to $1 billion after reporting about $260 million in third-quarter revenue, including $233 million in U.S. BRIUMVI net revenue. The shares rose 5.9% after earnings.

  • Management cited solid third-quarter performance and trends pointing to a strong fourth quarter as the basis for raising full-year revenue guidance.
  • About 35% of new anti-CD20 treatment starts are for self-administration, a segment BRIUMVI does not currently serve; the company expects Phase III results for subcutaneous BRIUMVI around year-end or early 2027 and is working toward a 2028 launch.
  • A Phase III study of a consolidated IV initiation dose was positive; TG is targeting potential approval around mid-2027.
  • The call highlighted early clinical results for azer-cel in progressive MS, while management also cited development programs in myasthenia gravis and treatment-resistant schizophrenia.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E21.75
EPS2.75
Book Value4.26
Price to Book14.05
Debt/Equity124.89
% Insiders7.469%
Growth
Revenue Growth0.70%
Earnings Growth-0.71%
Estimates
Forward P/E22.09
Forward EPS2.71
Target Mean Price69.71

DCF valuation

Model fair value for TG Therapeutics, Inc. (TGTX)
Result
Sign in to run the valuation for TGTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Strong buy · mean target 69.71 USD (low 21.00, high 86.00) · as of 9 Nov 2026
Low 21.00
Mean 69.71
High 86.00
Price 64.51
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

TG Therapeutics, Inc. Logo TG Therapeutics, Inc. Analysis (TGTX)

United States Health Care Official Website Stock

Is TG Therapeutics, Inc. a good investment? TG Therapeutics, Inc. (TGTX) is currently trading at 64.51 USD. Market analysts have a consensus price target of 69.71 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 21.75. This valuation is generally in line with the broader market.

Earnings Schedule: TG Therapeutics, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 2.71.

Investor FAQ

Does TG Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is TG Therapeutics, Inc.?

TG Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 2.75.

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Exchange Ticker
FRA (Germany) NKB2.F
NCM (Australia) TGTX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 29, 2003 1:5
July 14, 2011 1:50
April 30, 2012 0.0177778
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion